Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cystic Clear all
Completed Phase 4 Interventional Results available

Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings

NCT00685035
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
HFCWC with higher pressure/variable-frequency settings, HFCWC with lower pressure/mid-frequency settings
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 10, 2026, 11:54 PM EDT
Completed No phase listed Observational

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease

NCT01973192
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 4 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 10, 2026, 11:54 PM EDT
Enrolling by invitation No phase listed Observational

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

NCT03901521
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Desipramine

NCT01153542
View directory record Official record
Conditions
In Development for Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

NCT00509665
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
doxorubicin hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 10, 2026, 11:54 PM EDT
Completed No phase listed Observational

Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients

NCT02374411
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pancreatic Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma, Uterine Neoplasms
Interventions
Not listed
Lead sponsor
Edward Hospital
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 3 Interventional Results available

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

NCT00630812
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled mannitol, Placebo comparator
Drug
Lead sponsor
Syntara
Industry
Eligibility
6 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
28
States / cities
Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

NCT00889967
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin for Inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

NCT00572975
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Not applicable Interventional

Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis

NCT04687475
View directory record Official record
Conditions
Cystic Fibrosis, Lung Transplant; Complications
Interventions
Clinical Tool (Mobile Spirometry and Survey)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 11:54 PM EDT
Active, not recruiting Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 10, 2026, 11:54 PM EDT
Completed No phase listed Observational

Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease

NCT02142101
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 3 Interventional Results available

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00293462
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions
sargramostim, oral salt and soda mouthwash
Biological · Other
Lead sponsor
Marilyn Dodd
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 10, 2026, 11:54 PM EDT
Completed No phase listed Observational

A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida

NCT02198079
View directory record Official record
Conditions
Cystic Fibrosis, Pediatrics
Interventions
Sputum
Biological
Lead sponsor
University of Miami
Other
Eligibility
Up to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 10, 2026, 11:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)

NCT00590538
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sodium 4-Phenylbutyrate, Genistein (Unconjugated Isoflavones 100), Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

NCT00021333
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

NCT01531673
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

NCT03108131
View directory record Official record
Conditions
Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
Interventions
Atezolizumab, Cobimetinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 10, 2026, 11:54 PM EDT
Recruiting Phase 3 Interventional

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

NCT06996951
View directory record Official record
Conditions
Cystic Fibrosis (CF), Chronic Rhinosinusitis (CRS)
Interventions
STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID, CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID
Other · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 10, 2026, 11:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

NCT01916577
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Pulmonary Fibrosis
Interventions
Plerixafor mobilization of autologous CD117 stem cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 10, 2026, 11:54 PM EDT